Optimising levodopa therapy for the management of Parkinson's disease

Journal of Neurology

Volumn 252, Issue SUPPL. 4, 2005, Pages

  Stocchi, Fabrizio ^a  

^a IRCCS NEUROMED   (Italy)

Author keywords

CDS; Levodopa; Motor fluctuations; Parkinson's disease

Indexed keywords

LEVODOPA;

ANXIETY DISORDER; AREA UNDER THE CURVE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DYSKINESIA; HUMAN; INVOLUNTARY MOVEMENT; MOTOR DYSFUNCTION; NEUROTOXICITY; PANIC; PARKINSON DISEASE; PRIORITY JOURNAL; PULSATILE FLOW; SENSORY DYSFUNCTION; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; CLINICAL TRIALS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 26444616750     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-4009-4     Document Type: Conference Paper

References (72)

1. Agid Y, Olanow CW, et al. (2002) Levodopa: why the controversy? Lancet 360:575
2. Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16(3):448-458
3. Basma AN, Morris EJ, et al. (1995) L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 64(2):825-832
4. Benetello P, Furlanut M, et al. (1993) Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations. Eur Neurol 33(1):69-73
5. Brooks DJ, Sagar H (2003) Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 74(8):1071-1079
6. Calon F, Grondin R, et al. (2000) Molecular basis of levodopa-induced dyskinesias. Ann Neurol 47(4 Suppl 1):S70-S78
7. Chase TN (1998) The significance of continuous dopaminergic stimulation in the treatment of parkinson's disease. Drugs 55(S1 Suppl 1):S1-S9
8. Desagher S, Glowinski J, et al. (1996) Astrocytes protect neurons from hydrogen peroxide toxicity. J Neurosci 16(8):2553-2562
9. Fahn S, Oakes D, et al. (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351(24):2498-2508
10. Filion M, Tremblay L, et al. (1991) Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 547(1):152-161
11. Graham DG, Tiffany SM, et al. (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14:644-653
12. Han SK, Mytilineou C, et al. (1996) L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 66(2):501-510
13. Hauser RA (2004) Levodopa/carbidopa/entacapone (Stalevo). Neurology 62(1 Suppl 1):S64-S71
14. Hillen ME, Sage JI (1996) Nonmotor fluctuations in patients with Parkinson's disease. Neurology 47(5):1180-1183
15. Jankovic J (2002) Levodopa strengths and weaknesses. Neurology 58(4 Suppl 1):S19-S32
16. Jenner P (2004) Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 62(1 Suppl 1):S47-S55
17. Kaakkola S (2000) Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59(6):1233-1250
18. Koller W, Guarnieri M, et al. (2005) An open-label evaluation of the tolerability and safety of Stalevo(R) (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 112(2):221-230
19. Koller WC, Hutton JT, et al. (1999) Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 53(5):1012-1019
20. Koller WC, Pahwa R (1994) Treating motor fluctuations with controlled-release levodopa preparations. Neurology 44(7 Suppl 6):S23-S28
21. Koller WC, Tse W (2004) Unmet medical needs in Parkinson's disease. Neurology 62(1 Suppl 1):S1-S8
22. Lang AE, Lozano AM (1998) Parkinson's disease: second of two parts. N Engl J Med 339(16):1130-1143
23. Langeveld CH, Jongenelen CA, et al. (1995) Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal development. Neurosci Lett 192(1):13-16
24. Larsen JP, Worm-Petersen J, et al. (2003) The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 10(2):137-146
25. LeWitt PA, Nyholm D (2004) New developments in levodopa therapy. Neurology 62(1 Suppl 1):S9-S16
26. Ling ZD, Pieri SC, et al. (1996) Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons. Clin Neuropharmacol 19(4):360-365
27. Mena MA, Casarejos MJ, et al. (1996) Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity. Neuroreport 7(2):441-445
28. Mena MA, Casarejos MJ, et al. (1997) Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms. J Neural Transm 104(4-5):317-328
29. Mena MA, Pardo B, et al. (1992) Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 7(1):23-31
30. Mena MA, Pardo B, et al. (1993) Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid. Neuroreport 4(4):438-440
31. Mouradian MM, Kurth M (1990) Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 27(1):18-23
32. Muenter MD, Tyce GM (1971) L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 46(4):231-239
33. Myllylä V, Kaakkola S, Miettinen TE, Heikkinen H, Reinikainen K (2003) New triple combination of levodopa/ carbidopa/entacapone is a preferred treatment in patients with Parkinson's disease. Neurology 60(Suppl1):A289 (P04.064)
34. Myllyla V, Kultalahti ERV, et al. (2001) Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 8(1):53-60
35. Myllyla VV, Sotaniemi KA, et al. (1993) Effect of entacapone, a COMT inhibitor on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 45:419-423
36. Mytilineou C, Han S-K, et al. (1993) Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 61:1470-1478
37. Nutt JG, Woodward WR, et al. (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44(5):913-919
38. Oertel W, on behalf of the TC-INIT study group (2004) Stalevo (levodopa/carbidopa/entacapone) provides improved symptom control in fluctuating Parkinson's disease patients comparable to levodopa/DDCI given in combination with entacapone. Mov Disord 19(Suppl 9):P736
39. Obeso JA, Rodriguez-Oroz MC, et al. (2000) The evolution and origin of motor complications in Parkinson's disease. Neurology 55(11 Suppl 4):S13-S20; discussion S21-S23
40. Obeso JA, Rodriguez-Oroz MC, et al. (2000) Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 47(4 Suppl 1):S22-S32; discussion S32-S34
41. Olanow CW (2002) The role of dopamine agonists in the treatment of early Parkinson's disease. Neurology 58(4 Suppl 1):S33-S41
42. Olanow CW, Gauger LL, et al. (1991) Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol 29(5):556-559
43. Olanow CW, Obeso JA (2000) Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 55(11 Suppl 4):S72-S77; discussion S78-S81
44. Olanow CW, Watts RL, et al. (2001) An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56(11 Suppl 5):S1-S88
45. Olanow W, Schapira AH, et al. (2000) Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 23(10 Suppl):S117-S126
46. Pahwa R, Busenbark K, et al. (1993) Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 43(4):677-681
47. Pardo B, Mena MA, et al. (1993) Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord 8(3):278-284
48. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287(13):1653-1661
49. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 284(15):1931-1938
50. Parkinsons Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 42(5):747-755
51. Poewe W (2004) The role of COMT inhibition in the treatment of Parkinson's disease. Neurology 62(1 Suppl 1):S31-S38
52. Poewe WH, Deuschl G, et al. (2002) Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105(4):245-255
53. Rajput AH, Fenton ME, et al. (2002) Clinical-pathological study of levodopa complications. Mov Disord 17(2):289-296
54. Rascol O, Goetz C, et al. (2002) Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 359(9317):1589-1598
55. Rascol O, Brooks DJ, et al. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342(20):1484-1491
56. Rinne UK, Larsen JP, et al. (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51(5):1309-1314
57. Ruottinen HM, Rinne UK (1996) Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 60(1):36-40
58. Samii A, Nutt JG, et al. (2004) Parkinson's disease. Lancet 363(9423):1783-1793
59. Schapira AH, Olanow CW (2004) Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291(3):358-364
60. Stocchi F, Berardelli A, et al. (2003a) Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease. Clin Neuropharmacol 26(3):151-155
61. Stocchi F, Bramante L, et al. (1993) Apomorphine and lisuride infusion. A comparative chronic study. Adv Neurol 60:653-655
62. Stocchi F, Olanow CW (2004) Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 62(1 Suppl 1):S56-S63
63. Stocchi F, Ruggieri S, et al. (1988) Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration. J Neural Transm 27(Suppl):27-33
64. Stocchi F (2003) Is it possible to achieve continuous dopaminergic stimulation with oral levodopa doses plus entacapone? Presented at the AD/PD, Seville
65. Stocchi F, Battaglia G, et al. (2004) Clinical models of continuous dopaminergic stimulation. Neurology 19(Suppl 9):S435(P1277)
66. Stocchi F, Vacca L, et al. (2003b) Optimizing levodopa phamacokinetics in Parkinson's disease: the role of COMT inhibitor. Neurol Sci 24:217-218
67. Stocchi F, Vacca L, Ruggieri S, Olanow CW (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62(6):905-910
68. Swope DM (2004) Rapid treatment of "wearing off" in Parkinson's disease. Neurology 62(6 Suppl 4):S27-S31
69. Whone AL, Watts RL, et al. (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54(1):93-101
70. Widner H (2003) Strategies to modify levodopa treatment. Adv Neurol 91:229-236
71. Witjas T, Kaphan E, et al. (2002) Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59(3):408-413
72. Yeh KC, August TF, et al. (1989) Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 39(Suppl 2):25-38